# US 2026/0265215 A1 · Bckdk inhibitors and/or degraders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0265215 A1
- Document ID: US20260265215A1
- Status: Published application
- Kind: A1
- Application number: 19/338,116
- Filed: 2025-09-24
- Published: 2026-09-10
- Earliest claimed: 2021-12-01
- Assignees: Pfizer Inc.
- Applicants: Pfizer Inc.
- Inventors: Leanne Marie BUZON; Kimberly O'Keefe CAMERON; Kevin Francis DEBOYACE; Kevin James FILIPSKI; David Andrew GRIFFITH; Bethany Lyn KORMOS; Shenping LIU; Luis Angel MARTINEZ ALSINA; Matthew Richard REESE; Rachel Jane ROTH FLACH; Yuan ZHANG
- Web page: https://patentgrep.com/patent/US20260265215A1

## CPC

- C07D 333/68: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 333/70: attached in position 2
- A61K 31/381: having five-membered rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 13/12: of the kidneys
- C07D 307/85: attached in position 2
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Described herein are compounds of Formula I, wherein the variables are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors and/or degraders, pharmaceutical compositions containing such compounds and their use to treat, for example, diabetes, kidney disease, NASH and heart failure.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A compound of Formula I
or a pharmaceutically acceptable salt thereof, wherein:
Z is O;
A is
X1 is CR11;
each of R1, R3 and R4 are independently H;
R2 is fluoro or chloro;
each of R5, R6, R7, and R11 are independently selected from H, halo, hydroxyl, amino, cyano, (C1-C4)alkyl, (C3-C6)cycloalkyl, (C1-C4)alkoxy, (C1-C4)fluoroalkyl, (C3-C6) fluorocycloalkyl, (C1-C4)fluoroalkoxy, or (C1-C4)alkyl-(C1-C4)alkoxy; and
R10 is H;
wherein at least one of R5, R6, R7, R10 and R11 is other than H.

### Claim 22 (depends on 1)

The compound of claim 1, wherein R2 is fluoro.

### Claim 23 (depends on 1)

The compound of claim 1, wherein R5 is fluoro.

### Claim 24 (depends on 1)

The compound of claim 1, wherein R6 is (C1-C4)alkoxy.

### Claim 25 (depends on 1)

The compound of claim 1, wherein R11 is halo.

### Claim 26 (depends on 1)

The compound of claim 1, wherein R11 is fluoro.

### Claim 27 (depends on 1)

The compound of claim 1, wherein R7 is halo.

### Claim 28 (depends on 1)

The compound of claim 1, wherein R7 is fluoro.

### Claim 29 (depends on 1)

The compound of claim 1, wherein the compound is 6-fluoro-3-(2,4,5-trifluoro-3-methoxyphenyl)-1-benzofuran-2-carboxylic acid, or a pharmaceutically acceptable salt thereof.

### Claim 30 (depends on 1)

The compound of claim 1, wherein the compound is 6-chloro-3-(2,4,5-trifluoro-3-methoxyphenyl)-1-benzofuran-2-carboxylic acid, or a pharmaceutically acceptable salt thereof.

### Claim 31

A pharmaceutical composition comprising:
a) a therapeutically effective amount of a compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
Z is O;
A is
X1 is CR11;
each of R1, R3 and R4 are independently H;
R2 is fluoro or chloro;
each of R5, R6, R7, and R11 are independently selected from H, halo, hydroxyl, amino, cyano, (C1-C4)alkyl, (C3-C6)cycloalkyl, (C1-C4)alkoxy, (C1-C4)fluoroalkyl, (C3-C6) fluorocycloalkyl, (C1-C4)fluoroalkoxy, or (C1-C4)alkyl-(C1-C4)alkoxy; and
R10 is H;
wherein at least one of R5, R6, R7, R10 and R11 is other than H, and
b) a pharmaceutically acceptable carrier, vehicle, or diluent.

### Claim 32 (depends on 31)

The pharmaceutical composition of claim 31, wherein the pharmaceutical composition is formulated for oral administration.

### Claim 33 (depends on 31)

The pharmaceutical composition of claim 31, wherein the therapeutically effective amount is from about 1 mg to about 500 mg.

### Claim 34 (depends on 31)

The pharmaceutical composition of claim 31, wherein the compound is 6-fluoro-3-(2,4,5-trifluoro-3-methoxyphenyl)-1-benzofuran-2-carboxylic acid, or a pharmaceutically acceptable salt thereof.

### Claim 35 (depends on 31)

The pharmaceutical composition of claim 31, wherein the compound is 6-chloro-3-(2,4,5-trifluoro-3-methoxyphenyl)-1-benzofuran-2-carboxylic acid, or a pharmaceutically acceptable salt thereof.

### Claim 36

A method of treating a condition, comprising administering a therapeutically effective amount of a compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
Z is O;
A is
X1 is CR11;
each of R1, R3 and R4 are independently H;
R2 is fluoro or chloro;
each of R5, R6, R7, and R11 are independently selected from H, halo, hydroxyl, amino, cyano, (C1-C4)alkyl, (C3-C6)cycloalkyl, (C1-C4)alkoxy, (C1-C4)fluoroalkyl, (C3-C6) fluorocycloalkyl, (C1-C4)fluoroalkoxy, or (C1-C4)alkyl-(C1-C4)alkoxy; and
R10 is H;
wherein at least one of R5, R6, R7, R10 and R11 is other than H,
wherein the condition is selected from the group consisting of: fatty liver, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, nonalcoholic steatohepatitis with liver fibrosis, nonalcoholic steatohepotitis with cirrhosis, nonalcoholic steatohepatitis with cirrhosis and hepatocellular carcinoma, treating or reducing the risk of hospitalization for heart failure, cardiovascular death, congestive heart failure, heart failure with New York Heart Association Class I-IV symptoms, heart failure with reduced left ventricular function (HF-rEF), heart failure with preserved left ventricular function (HF-pEF), heart failure with midrange ejection fraction (HF-mrEF), cardiovascular death, heart failure in patients with Type II diabetes mellitus, coronary heart disease, unstable angina, peripheral arterial disease peripheral vascular disease, renovascular disease, pulmonary hypertension, vasculitis, acute coronary syndromes, modification of cardiovascular risk, Type I diabetes, Type II diabetes mellitus, idiopathic Type I diabetes (Type Ib), latent autoimmune diabetes in adults (LADA), early-onset Type 2 diabetes (EOD), youth-onset atypical diabetes (YOAD), maturity onset diabetes of the young (MODY), malnutrition-related diabetes, gestational diabetes, coronary heart disease, ischemic stroke, restenosis after angioplasty, peripheral vascular disease, intermittent claudication, myocardial infarction, dyslipidemia, post-prandial lipemia, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose, metabolic acidosis, ketosis, arthritis, diabetic retinopathy, macular degeneration, cataract, diabetic nephropathy, glomerulosclerosis, chronic renal failure, diabetic neuropathy, metabolic syndrome, syndrome X, hyperglycemia, hyperinsulinemia, hypertriglyceridemia, insulin resistance, impaired glucose metabolism, skin and connective tissue disorders, foot ulcerations and ulcerative colitis, endothelial dysfunction and impaired vascular compliance, hyper apo B lipoproteinemia, kidney disease, end-stage kidney disease, chronic kidney disease at risk of progression, maple syrup urine disease, hepatocellular carcinoma, kidney renal clear cell carcinoma, head and neck squamous cell carcinoma, colorectal adenocarcinoma, mesothelioma, stomach adenocarcinoma, adrenocortical carcinoma, kidney papillary cell carcinoma, cervical and endocervical carcinoma, bladder urothelial carcinoma, and lung adenocarcinoma.

### Claim 37 (depends on 36)

The method of claim 36, wherein the condition is heart failure.

### Claim 38 (depends on 36)

The method of claim 36, wherein the condition is chronic kidney disease.

### Claim 39 (depends on 36)

The method of claim 36, wherein the therapeutically effective amount is from about 1 mg to about 500 mg.

### Claim 40 (depends on 36)

The method of claim 36, wherein the pharmaceutical composition is formulated for oral administration.
